Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
83
datasets available to search
ShareScore release 0.9.0
Dataset results
83 results for “Transthyretin amyloidosis”
Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients
ClinicalTrials.gov study NCT05075798. IPD Sharing: Not stated. Countries: 1. Publications: 5.
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
ClinicalTrials.gov study NCT06345235. IPD Sharing: NO. Countries: 1. Publications: 6.
Quantitative-imaging in Cardiac Transthyretin Amyloidosis
ClinicalTrials.gov study NCT05776212. IPD Sharing: YES. Countries: 1. Publications: 1.
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
ClinicalTrials.gov study NCT06034405. IPD Sharing: UNDECIDED. Countries: 1. Publications: 64.
The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.
ClinicalTrials.gov study NCT05814380. IPD Sharing: NO. Countries: 1. Publications: 3.
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Trans
ClinicalTrials.gov study NCT04601051. IPD Sharing: Not stated. Countries: 4. Publications: 4.
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
ClinicalTrials.gov study NCT06465810. IPD Sharing: YES. Countries: 5. Publications: 1.
A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
ClinicalTrials.gov study NCT05442047. IPD Sharing: YES. Countries: 10. Publications: 2.
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT01623245. IPD Sharing: Not stated. Countries: 1. Publications: 9.
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ClinicalTrials.gov study NCT06679946. IPD Sharing: YES. Countries: 16. Publications: 1.
Comprehensive Program for Hereditary Transthyretin Amyloidosis
ClinicalTrials.gov study NCT07213297. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis
ClinicalTrials.gov study NCT03336580. IPD Sharing: NO. Countries: 4. Publications: 1.
EFICAC-TTR Trial: Exercise and Nutritional Supplementation in Transthyretin Cardiac Amyloidosis
ClinicalTrials.gov study NCT07343999. IPD Sharing: YES. Countries: 0. Publications: 5.
Neurofilament light chain (NfL) as a biomarker of hereditary transthyretin-mediated amyloidosis
<p>To identify changes in the proteome associated with onset and progression of ATTRv amyloidosis, we performed an observational, case-controlled study which compared proteomes of patients with ATTRv amyloidosis and healthy controls.</p> <p>Plasma levels of >1,000 proteins were measured in patients with ATTRv amyloidosis with polyneuropathy who received either placebo or patisiran in the APOLLO study and in healthy controls. The impact of patisiran on the time profile of each protein was determined by linear mixed model at 0, 9, and 18 months. Neurofilament light chain (NfL) was further assessed using an orthogonal quantitative approach.</p> <p>Levels of 66 proteins were significantly changed with patisiran vs placebo, with NfL change most significant (p < 10<sup>−20</sup>). Analysis of changes in protein levels demonstrated that the proteome of patisiran-treated patients trended toward healthy controls at 18 months. Healthy controls' NfL levels were 4-fold lower than in patients with ATTRv amyloidosis with polyneuropathy (16.3 vs 69.4 pg/mL, effect: −53.1 pg/mL, 95% CI [–60.5 to −45.9]). NfL levels at 18 months increased with placebo (99.5 vs 63.2 pg/mL, 36.3 pg/mL, [16.5–56.1]) and decreased with patisiran treatment (48.8 vs 72.1 pg/mL, −23.3 pg/mL, [–33.4 to −13.1]) from baseline. At 18 months, improvement in modified Neuropathy Impairment Score +7 following patisiran significantly correlated with reduced NfL (R = 0.43, [0.29–0.55]).</p> <p>Findings suggest NfL may serve as a biomarker of nerve damage and polyneuropathy in ATTRv amyloidosis, may enable earlier diagnosis of patients with ATTRv amyloidosis, and facilitate monitoring of disease progression.</p> <p>This study provides Class III evidence that NfL levels may enable earlier diagnosis of polyneuropathy in patients with ATTRv amyloidosis and facilitate monitoring of disease progression.</p>
Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
ClinicalTrials.gov study NCT05560555. IPD Sharing: NO. Countries: 1. Publications: 0.
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
ClinicalTrials.gov study NCT02292186. IPD Sharing: Not stated. Countries: 3. Publications: 0.
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
ClinicalTrials.gov study NCT02595983. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Neurofilament light chain (NfL) as a biomarker of hereditary transthyretin-mediated amyloidosis
Open the record for dataset details and reuse information.
Circulating microRNAs profile in patients with transthyretin variant amyloidosis
GEO Series GSE149665. Homo sapiens. 40 samples. Type: Non-coding RNA profiling by array.
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
ClinicalTrials.gov study NCT03431896. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.